Press

Mindset Pharma Receives Notice of Allowance for Patent Application for Psilocin Derivatives

Jun 13 • 2 min read

Mindset Pharma Inc. (CSE: MSET | FSE: 9DF | OTCQB: MSSTF), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, announced that the United States Patent and Trademark Office (‘USPTO’) has issued a Notice of Allowance for Mindset’s patent application…

Nova Mentis and University of Central Florida to Develop Saliva Serotonin Assay

Jun 10 • 3 min read

Nova Mentis Life Science Corp. (CSE: NOVA | FSE: HN3Q | OTCQB: NMLSF), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to announce that it has signed a research agreement with the University of Central Florida (UCF) Research Foundation to develop a saliva serotonin assay….

Tryp Therapeutics Announces Results of First Patient Dosed in Phase II Clinical Trial for Binge Eating Disorder

Jun 9 • 4 min read

Tryp Therapeutics, Inc. (CSE: TRYP | OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today the initial data readout for the first patient dosed in its Phase II S.T.O.P. (Study of the Treatment of Overeating utilizing Psilocybin) trial. In collaboration with the University of Florida….

Nova Mentis Receives Controlled Substances Export Approval From DEA For Proprietary Psilocybin Drug

Jun 8 • 2 min read

Nova Mentis Life Science Corp. (CSE: NOVA | FSE: HN3Q | OTCQB: NMLSF), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce it received the required controlled substances export approval from the DEA. The Company’s proprietary psilocybin drug (NM-1001), has been received at the…

Cybin Acquires DMT Clinical Study from Entheon Biomedical

Jun 7 • 4 min read

Cybin Inc. (NEO: CYBN | NYSE:CYBN), a biopharmaceutical company, today announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has entered into an agreement to acquire a Phase 1 N,N-dimethyltryptamine (DMT) study from Entheon Biomedical Corp. (CSE: ENBI | OTCQB: ENTBF | FSE: 1XU1) to accelerate the clinical development path for CYB004, Cybin’s proprietary…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435